Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis

Part of paid clinical trials in Fremont, California.

Sponsor
Novartis Pharmaceuticals
Study ID
NCT07220577
Phase
PHASE2
Status
Active Not Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 100 Years
Healthy Volunteers
Not accepted

Interventions

  • GIA632 — DRUG
    Active treatment arm
  • Placebo — OTHER
    Placebo treatment arm

Study Details

The main purpose of this Ph2a study is to evaluate the preliminary efficacy, safety and tolerability of GIA632 when administered to adult participants with moderate to severe atopic dermatitis (AD).

Key Dates

Start date
Nov 10, 2025
Status verified
May 2026
Primary completion
May 17, 2027
Completion
Sep 6, 2027

Study Design

Enrollment
34 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: GIA632
    Active treatment arm
  • Placebo Comparator: Placebo
    Placebo treatment arm

Primary Outcome Measure

IGA response at Week 16 defined as clear (0) or almost clear (1) score with at least a 2 point-reduction from baseline [ Time Frame: Baseline, Week 16 ]

Locations (3)

FacilityCityStateZIPSite coordinators
Ctr for Dermatology Clinical ResFremontCalifornia95438-
Aesthetics Skin Care Dermatologic SurgeryRockvilleMaryland20850-
Care Access HobokenHobokenNew Jersey07030-

Find similar trials in Fremont, CA

By condition
Atopic dermatitis / eczema
By specialty
DermatologyRheumatologyAutoimmune disease
By research site
Ctr for Dermatology Clinical Res· Fremont, CAAesthetics Skin Care Dermatologic Surgery· Rockville, MDCare Access Hoboken· Hoboken, NJ

Related Studies